|
|
Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease |
Yong Lin, Li Li, Jia Qu |
Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China |
|
|
Abstract Histone acetylation is an important modification of proteins in cell biology, occurring as a post-translational modification (PTM). It participates in chromosome remodeling, which is maintained by histone acetyltransferase (HATs) and histone deacetylase (HDACs). HDAC inhibitors (HDACis) act specifically against several types of HDACs, causing increased acetylation of histone and non-histone proteins. HDACis induce cell cycle arrest, differentiation, apoptosis and migration. Several HDACis have been approved for clinical trials to treat cancer. HDACs have been detected extensively in eye tissue, indicating they have important roles in the occurrence and development of eye diseases. In this review, we summarize current knowledge concerning the roles of HDACis in eye diseases, aiming to make their applications possible in the clinical treatment of eye diseases in the future.
|
Received: 12 November 2018
|
Fund:Foundation of Wenzhou Science & Technology Bureau (2017Y0918); Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018KY132) |
Corresponding Authors:
Jia Qu, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China (Email: jqu@wzmc.net)
|
|
|
|
[1] |
Holliday R. Epigenetics: A historical overview. Epigenetics, 2006, 1(2): 76-80.
|
[2] |
Mazzio EA, Soliman KF. Basic concepts of epigenetics: impact of environmental signals on gene expression. Epigenetics, 2012, 7(2): 119-130. DOI: 10.4161/epi.7.2.18764.
|
[3] |
Kouzarides T. Chromatin modifications and their function. Cell, 2007, 128(4): 693-705. DOI: 10.1016/j.cell.2007.02.005.
|
[4] |
Luger K, M?der AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997, 389(6648): 251-260. DOI: 10.1038/38444.
|
[5] |
Verdin E, Ott M. 50 years of protein acetylation: From gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol, 2015, 16(4): 258-264. DOI: 10.1038/nrm3931.
|
[6] |
Eslaminejad MB, Fani N, Shahhoseini M. Epigenetic regulation of osteogenic and chondrogenic differentiation of mesenchymal stem cells in culture. Cell J, 2013, 15(1): 1-10.
|
[7] |
Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J, 2003, 22(5): 1168-1179. DOI: 10.1093/emboj/cdg115.
|
[8] |
Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 2005, 280(29): 26729-26734. DOI: 10.1074/jbc.C500186200.
|
[9] |
Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol, 2011, 2011: 371832. DOI: 10.1155/2011/371832.
|
[10] |
Khan O, La Thangue NB. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol, 2012, 90(1): 85-94. DOI: 10.1038/icb.2011.100.
|
[11] |
Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res, 2007, 5(10): 981-989. DOI: 10.1158/1541-7786.MCR-07-0324.
|
[12] |
Giannini G, Cabri W, Fattorusso C, et al. Histone deacetylase inhibitors in the treatment of cancer: Overview and perspectives. Future Med Chem, 2012, 4(11): 1439-1460. DOI: 10.4155/Fmc. 12.80.
|
[13] |
Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol, 2012, 6(6): 579-589. DOI: 10.1016/j.molonc.2012. 07.003.
|
[14] |
Yang XJ, Grégoire S. Class Ⅱ histone deacetylases: From sequence to function, regulation, and clinical implication. Mol Cell Biol, 2005, 25(8): 2873-2884. DOI: 10.1128/MCB.25.8. 2873-2884.2005.
|
[15] |
Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors. Anticancer Drugs, 2014, 25(2): 140-149. DOI: 10. 1097/CAD.0000000000000040.
|
[16] |
Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res, 2009, 15(12): 3958-3969. DOI: 10.1158/1078-0432.CCR-08-2785.
|
[17] |
Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res, 2015, 49: 17-45. DOI: 10.1016/j.preteyeres.2015.07.002.
|
[18] |
Tandon A, Tovey JC, Sharma A, et al. Role of transforming growth factor Beta in corneal function, biology and pathology. Curr Mol Med, 2010, 10(6): 565-578.
|
[19] |
Zhou Q, Wang Y, Yang L, et al. Histone deacetylase inhibitors blocked activation and caused senescence of corneal stromal cells. Mol Vis, 2008, 14: 2556-2565.
|
[20] |
Wang J, Lin A, Lu L. Effect of EGF-induced HDAC6 activation on corneal epithelial wound healing. Invest Ophthalmol Vis Sci, 2010, 51(6): 2943-2948. DOI: 10.1167/iovs.09-4639.
|
[21] |
Sharma A, Mehan MM, Sinha S, et al. Trichostatin a inhibits corneal haze in vitro and in vivo. Invest Ophthalmol Vis Sci, 2009, 50(6): 2695-2701. DOI: 10.1167/iovs.08-2919.
|
[22] |
Sharma A, Sinha NR, Siddiqui S, et al. Role of 5' TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated corneal fibrosis inhibition. Molecular Vis, 2015, 21: 974-984.
|
[23] |
Donnelly KS, Giuliano EA, Sharma A, et al. Suberoylanilide hydroxamic acid (vorinostat): Its role on equine corneal fibrosis and matrix metalloproteinase activity. Vet Ophthalmol, 2014, 17: 61-68. DOI: 10.1111/vop.12129.
|
[24] |
Tandon A, Tovey JC, Waggoner MR, et al. Vorinostat: A potent agent to prevent and treat laser-induced corneal haze. J Refract Surg, 2012, 28(4): 285-290. DOI: 10.3928/1081597X-20120210-01.
|
[25] |
Lim RR, Tan A, Liu YC, et al. ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis. Sci Rep, 2016, 6: 20841. DOI: 10.1038/srep20841.
|
[26] |
杜文文, 张凤妍. 后发性白内障与相关信号通路的研究进展. 国际眼科纵览, 2016, 40(3): 170-178. DOI: 10.3706/cma.j.issn. 1673-5803.2016.03.006.
|
[27] |
Meacock WR, Spalton DJ, Stanford MR. Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol, 2000, 84(3): 332-336.
|
[28] |
Yang Y, Ye Y, Lin X, et al. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01/04. PLoS One, 2013, 8(2): e56837. DOI: 10.1371/journal.pone.0056837.
|
[29] |
Rong X, Qiu X, Jiang Y, et al. Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract. Sci Rep, 2016, 6: 34704. DOI: 10.1038/srep34704.
|
[30] |
Chen X, Xiao W, Chen W, et al. The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis, 2013, 4: e884. DOI: 10.1038/cddis.2013.416.
|
[31] |
Xie L, Santhoshkumar P, Reneker LW, et al. Histone deacetylase inhibitors trichostatin A and vorinostat inhibit TGFβ2-induced lens epithelial-to-mesenchymal cell transition. Invest Ophthalmol Vis Sci, 2014, 55(8): 4731-4740. DOI: 10.1167/iovs.14-14109.
|
[32] |
Tovar-Vidales T, Clark AF, Wordinger RJ. Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. Exp Eye Res, 2011, 93(4): 442-451. DOI: 10.1016/j.exer.2011.06.011.
|
[33] |
Wordinger RJ, Fleenor DL, Hellberg PE, et al. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: Implications for glaucoma. Invest Ophthalmol Vis Sci, 2007,48(3): 1191-1200. DOI: 10.1167/iovs.06-0296.
|
[34] |
Bermudez JY, Webber HC, Patel GC, et al. HDAC inhibitor-mediated epigenetic regulation of glaucoma-associated TGFβ2 in the trabecular meshwork. Invest Ophthalmol Vis Sci, 2016, 57(8): 3698-3707. DOI: 10.1167/iovs16-19446.
|
[35] |
Schwechter BR, Millet LE, Levin LA. Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and
|
|
interaction with survival. Invest Ophthalmol Vis Sci, 2007, 48(6): 2845-2857. DOI: 10.1167/iovs.06-1364.
|
[36] |
Kimura A, Guo X, Noro T, et al. Valproic acid prevents retinal degeneration in a murine model of normal tension glaucoma. Neurosci Lett, 2015, 588: 108-113. DOI: 10.1016/j.neulet.2014. 12.054.
|
[37] |
Biermann J, Grieshaber P, Goebel U, et al. Valproic acidmediated neuroprotection and regeneration in injured retinal ganglion cells. Invest Ophthalmol Vis Sci, 2010, 51(1): 526-534. DOI: 10.1167/iovs.09-3903.
|
[38] |
Biermann J, Boyle J, Pielen A, et al. Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells. Mol Vis, 2011, 17: 395-403.
|
[39] |
Pelzel HR, Schlamp CL, Nickells RW. Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis. BMC Neurosci, 2010, 11: 62. DOI: 10.1186/1471-2202-11-62.
|
[40] |
Schmitt HM, Pelzel HR, Schlamp CL, et al. Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury. Mol Neurodegener, 2014, 9: 39. DOI: 10.1186/1750-1326-9-39.
|
[41] |
Lebrun-Julien F, Suter U. Combined HDAC1 and HDAC2 depletion promotes retinal ganglion cell survival after injury through reduction of p53 target gene expression. ASN Neuro, 2015, 7(3). DOI: 10.1177/1759091415593066.
|
[42] |
Bradley JE, Ramirez G, Hagood JS. Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. Biofactors, 2009, 35(3): 258-265. DOI: 10.1002/biof.41.
|
[43] |
Chindasub P, Lindsey JD, Duong-Polk K, et al. Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells. Invest Ophthalmol Vis Sci, 2013, 54(1): 96-102. DOI: 10.1167/iovs.12-10850.
|
[44] |
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
|
[45] |
Yokoi M, Yamagishi SI, Takeuchi M, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol, 2005, 89(6): 673-675. DOI: 10.1136/bjo.2004.055053.
|
[46] |
Dahrouj M, Alsarraf O, McMillin JC, et al. Vascular endothelial growth factor modulates the function of the retinal pigment epithelium in vivo. Invest Ophthalmol Vis Sci, 2014, 55(4): 2269-2275. DOI: 10.1167/iovs.13-13334.
|
[47] |
Desjardins D, Liu Y, Crosson CE, et al. Histone deacetylase inhibition restores retinal pigment epithelium function in hyperglycemia. PLoS One, 2016, 11(9): e0162596. DOI: 10.1371/journal.pone.0162596.
|
[48] |
Zhong Q, Kowluru RA. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem, 2010, 110(6): 1306-1313. DOI: 10.1002/jcb.22644.
|
[49] |
Kadiyala CS, Zheng L, Du Y, et al. Acetylation of retinal histones in diabetes increases inflammatory proteins: Effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem, 2012, 287(31): 25869-25880. DOI: 10.1074/jbc.M112.375204.
|
[50] |
Xie M, Tian J, Luo Y, et al. Effects of 5-aza-2'-deoxycytidine and trichostatin A on high glucose- and interleukin-1β-induced secretory mediators from human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis, 2014, 20: 1411-1421.
|
[51] |
Kim JH, Kim JH, Oh M, et al. N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis. Mol Pharm, 2009, 6(2): 513-519. DOI: 10.1021/mp800178b.
|
[52] |
Sancho-Pelluz J, Arango-Gonzalez B, Kustermann S, et al. Photoreceptor cell death mechanisms in inherited retinal degeneration. Mol Neurobiol, 2008, 38(3): 253-269. DOI: 10.1007/s12035-008-8045-9.
|
[53] |
Dryja TP, Rucinski DE, Chen SH, et al. Frequency of mutations in the gene encoding the alpha subunit of rod cGMP-phosphodiesterase in autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci, 1999, 40(8): 1859-1865.
|
[54] |
Paquet-Durand F, Silva J, Talukdar T, et al. Excessive activation of poly (ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse. J Neurosci, 2007, 27(38): 10311-10319. DOI: 10.1523/JNEUROSCI.1514-07.2007.
|
[55] |
De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol, 2012, 84(2): 137-146. DOI: 10.1016/j.bcp.2012.03.018.
|
[56] |
Sancho-Pelluz J, Alavi MV, Sahaboglu A, et al. Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death Dis, 2010, 1: e24. DOI: 10.1038/cddis.2010.4.
|
[57] |
Guo X, Wang SB, Xu H, et al. A short N-terminal domain of HDAC4 preserves photoreceptors and restores visual function in retinitis pigmentosa. Nat Commun, 2015, 6: 8005. DOI: 10. 1038/ncomms9005.
|
[58] |
Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science, 2009, 323(5911): 256-259. DOI: 10.1126/science.1166226.
|
[59] |
Mitton KP, Guzman AE, Deshpande M, et al. Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration mice. Mol Vis, 2014, 20: 1527-1544.
|
[60] |
Clemson CM, Tzekov R, Krebs M, et al. Therapeutic potential of valproic acid for retinitis pigmentosa. Br J Ophthalmol, 2011, 95(1): 89-93. DOI: 10.1136/bjo.2009.175356.
|
[61] |
Iraha S, Hirami Y, Ota S, et al. Efficacy of valproic acid for retinitis pigmentosa patients: A pilot study. Clin Ophthalmol, 2016, 10: 1375-1384. DOI: 10.2147/OPTH.S109995.
|
[62] |
Shanmugam PM, Minija CK, Ramanjulu R, et al. Effect of short-term oral valproic Acid on vision and visual field in retinitis pigmentosa. Ophthalmol Ther, 2012, 1(1): 6. DOI: 10.1007/s40123-012-0006-8.
|
[63] |
Feng W, Zhang B, Cai D, et al. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett, 2014, 347(2): 183-190. DOI: 10.1016/j.canlet.2014.02.012.
|
[64] |
Khabele D. The therapeutic potential of class Ⅰ selective histone deacetylase inhibitors in ovarian cancer. Front Oncol, 2014, 4: 111. DOI: 10.3389/fonc.2014.00111.
|
[65] |
Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics, 2008, 3(1): 28-37.
|
[66] |
Chuang MJ, Wu ST, Tang SH, et al. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS One, 2013, 8(9): e73401. DOI: 10.1371/journal.pone.0073401.
|
[67] |
Russo D, Durante C, Bulotta S, et al. Targeting histone deacetylase in thyroid cancer. Expert Opin Ther Targets, 2013, 17(2): 179-193. DOI: 10.1517/14728222.2013.740013.
|
[68] |
Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science, 2010, 330(6009): 1410-1413. DOI: 10.1126/science.1194472.
|
[69] |
Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res, 2012, 18(2): 408-416. DOI: 10.1158/1078-0432.CCR-11-0946.
|
[70] |
Klisovic DD, Katz SE, Effron D, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci, 2003, 44(6): 2390-2398.
|
[71] |
Munoz-Erazo L, Madigan M, Conway RM. Gene expression in conjunctival melanoma cell lines treated with the histone deacetylase (HDAC) inhibitor valproic acid (VPA). Acta Ophthalmologica, 2014, 92. DOI: 10.1111/j.1755-3768.2014. 4446.x.
|
[72] |
Venza I, Visalli M, Oteri R, et al. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol, 2014, 21(2): 439-446. DOI: 10.1016/j.intimp.2014.05.024.
|
[73] |
Harbour JW, Chao DL. A molecular revolution in uveal melanoma: Implications for patient care and targeted therapy. Ophthalmology, 2014, 121(6): 1281-1288. DOI: 10.1016/j.ophtha. 2013.12.014.
|
[74] |
邹宏密, 简嘉, 周希媛. 视网膜母细胞瘤的治疗研究进展. 国际眼科杂志, 2018, 18(8): 1407-1410. DOI: 10.3980/j.issn.
|
16 |
72-5123.2018.8.11.
|
[75] |
Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell, 1998, 92(4): 463-473.
|
[76] |
Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature, 1998, 391(6667): 597-601. DOI: 10.1038/35404.
|
[77] |
Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res, 2008, 14(10): 3113-3123. DOI: 10.1158/1078-0432.CCR-07-4836.
|
[78] |
Poulaki V, Mitsiades CS, Kotoula V, et al. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: Clinical implications. Invest Ophthalmol Vis Sci, 2009, 50(9): 4072-4079. DOI: 10.1167/iovs.09-3517.
|
|
|
|